Drugs for Neglected Diseases initiative - DNDi
Séverine BLESSON has extensive experience in clinical research, project leadership, and scientific program management. Séverine has held various roles at DNDi, ANRS, and Institut Gustave Roussy, with a background in veterinary medicine and a focus on immunology and oncology. Séverine is skilled in study design, pharmacovigilance, and coordinating multi-country trials in diverse patient populations. Additionally, Séverine has experience in basic research and non-clinical studies in pharmaceutical settings.
Drugs for Neglected Diseases initiative - DNDi
2 followers
The Drugs for Neglected Diseases initiative (DNDi) is an international, not-for-profit research and development organization. We discover, develop, and deliver treatments for neglected patients around the world. Our treatments are affordable and patient-friendly – and have already saved millions of lives. We are researching new treatments for people living with Chagas disease, sleeping sickness (human African trypanosomiasis), leishmaniasis, filarial infections, mycetoma, paediatric HIV, hepatitis C, and dengue. Together with our partners, we are working on over 40 projects, including more than 20 new chemical entities. We are also running over 20 clinical trials. When the medical humanitarian organization Médecins Sans Frontières (MSF) won the Nobel Peace Prize in 1999, they dedicated a portion of the award to addressing this fatal imbalance and exploring a new, alternative, not-for-profit model for developing drugs for neglected patients. As a result in 2003, MSF, the World Health Organization, and five international research institutions founded DNDi.